{"product_id":"iba-worldwide-bcg-matrix","title":"IBA Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVisual. Strategic. Downloadable.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eCurious about the strategic positioning of a company's product portfolio? The BCG Matrix offers a powerful framework to categorize products as Stars, Cash Cows, Dogs, or Question Marks, guiding critical investment decisions. This glimpse provides a foundational understanding, but imagine unlocking the full potential of this analysis.\u003c\/p\u003e\n\u003cp\u003eTo truly leverage the BCG Matrix for your business, you need the complete picture. Purchase the full report to gain detailed quadrant placements, actionable insights, and a clear roadmap for optimizing your product strategy and resource allocation. Don't just understand the theory; implement it for tangible results.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarket Leadership in Proton Therapy Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIBA stands as the undisputed global leader in the proton therapy systems market. In 2024, the company captured an impressive 60% of all new systems sold, underscoring its market dominance. This strong performance translates to a substantial 42% share of all operational proton therapy rooms worldwide, highlighting IBA's extensive reach and impact.\u003c\/p\u003e\n\u003cp\u003eThe company's success is largely driven by its highly regarded Proteus®ONE and Proteus®PLUS systems. These innovative solutions are deployed across numerous healthcare facilities globally, reinforcing IBA's robust competitive edge in this advanced medical technology sector.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Growth in Proton Therapy Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe proton therapy market is booming, with a projected growth from USD 572.5 million in 2024 to almost USD 2 billion by 2034. This represents a substantial Compound Annual Growth Rate (CAGR) of 10.9% to 13.3% from 2025 to 2034, fueled by rising cancer rates and better treatment tech. IBA's strong market position and ongoing innovation place it perfectly to benefit from this expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Backlog and Order Intake in Proton Therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIBA's proton therapy division is a star performer, evidenced by its impressive all-time high equipment and services backlog reaching €1.5 billion as of May 2025. This substantial figure translates directly into strong revenue visibility for the foreseeable future.\u003c\/p\u003e\n\u003cp\u003eThe backlog is bolstered by 38 active proton therapy projects, including numerous Proteus®ONE and Proteus®PLUS systems, showcasing the company's ongoing market penetration and successful project execution.\u003c\/p\u003e\n\u003cp\u003eRobust commercial momentum, especially in key growth markets like Asia-Pacific and the United States, fuels a consistent conversion of its sales pipeline and the acquisition of new orders, ensuring sustained revenue generation for this high-growth segment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContinuous Innovation in Proton Therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIBA's commitment to continuous innovation in proton therapy is a key driver of its market position. The company consistently invests in research and development, focusing on advancements like DynamicARC® and ConformalFLASH®. These technologies are designed to boost treatment accuracy and speed, solidifying IBA's technological leadership.\u003c\/p\u003e\n\u003cp\u003eThis dedication to product evolution keeps IBA's proton therapy systems competitive and attractive to new clients, broadening the potential uses for this advanced cancer treatment. For instance, IBA reported a significant increase in its order backlog for proton therapy centers in 2023, reaching over €1 billion, underscoring the market demand for their innovative solutions.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eDynamicARC®:\u003c\/strong\u003e Enhances treatment delivery speed and patient comfort by enabling continuous beam delivery during patient movement.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eConformalFLASH®:\u003c\/strong\u003e Aims to further reduce treatment time and potential side effects through ultra-fast dose delivery.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eR\u0026amp;D Investment:\u003c\/strong\u003e IBA's ongoing investment in R\u0026amp;D, which represented a substantial portion of their revenue in recent years, fuels these advancements.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Expansion:\u003c\/strong\u003e These innovations are crucial for expanding the reach and application of proton therapy in oncology.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Expansion in Key Geographies for PT\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePT is strategically expanding its presence in key growth regions. The company has a robust development pipeline featuring new proton therapy projects across the United States and various Asian markets, indicating a forward-looking approach to market penetration. \u003c\/p\u003e\n\u003cp\u003eRecent successful ventures underscore this expansion, including significant contracts for its Proteus®ONE systems in India. These partnerships with prominent healthcare providers like AIG and Apollo Hospitals highlight PT's ability to establish strong market footholds and broaden its collaborative network. \u003c\/p\u003e\n\u003cp\u003eThis deliberate geographical diversification, coupled with focused engagement with strategic clients, is fundamental to maintaining PT's leadership position and capitalizing on global growth prospects. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eGeographic Focus:\u003c\/strong\u003e United States and Asia represent key expansion areas.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eKey Partnerships:\u003c\/strong\u003e Contracts with AIG and Apollo Hospitals in India for Proteus®ONE systems.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStrategic Goal:\u003c\/strong\u003e Sustain market leadership and capture worldwide growth opportunities.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIBA's Proton Therapy: A Shining Star\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIBA's proton therapy division is a clear star in the BCG matrix, demonstrating high market share in a rapidly growing industry. Its dominance is evident in the 2024 market, where it secured 60% of new system sales and holds 42% of all operational proton therapy rooms globally. This strong position is supported by a substantial backlog of €1.5 billion as of May 2025, stemming from 38 active projects.\u003c\/p\u003e\n\u003cp\u003eThe company's innovative Proteus®ONE and Proteus®PLUS systems, along with advancements like DynamicARC® and ConformalFLASH®, solidify its technological leadership and appeal. With the proton therapy market projected to grow significantly, IBA is well-positioned to leverage its star status for continued success.\u003c\/p\u003e\n\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025 Data\u003c\/th\u003e\n\u003cth\u003eSignificance\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Share (New Systems Sold)\u003c\/td\u003e\n\u003ctd\u003e60% (2024)\u003c\/td\u003e\n\u003ctd\u003eDominant position in a growing market\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal Operational Rooms Share\u003c\/td\u003e\n\u003ctd\u003e42%\u003c\/td\u003e\n\u003ctd\u003eExtensive market penetration\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBacklog (May 2025)\u003c\/td\u003e\n\u003ctd\u003e€1.5 billion\u003c\/td\u003e\n\u003ctd\u003eStrong revenue visibility\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eActive Projects\u003c\/td\u003e\n\u003ctd\u003e38\u003c\/td\u003e\n\u003ctd\u003eDemonstrates ongoing demand and execution\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Growth (2024-2034)\u003c\/td\u003e\n\u003ctd\u003e10.9% to 13.3% CAGR\u003c\/td\u003e\n\u003ctd\u003eIndicates significant future expansion potential\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eThe IBA BCG Matrix offers a strategic framework to analyze a company's product portfolio, categorizing units by market share and growth rate to guide investment decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eClear visualization of your portfolio's strengths and weaknesses, simplifying strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished Dosimetry Market Position\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIBA holds a strong position in the dosimetry market, offering crucial quality assurance tools for radiation therapy.  In FY 2024, this segment generated €65.9 million in revenue, demonstrating stable performance in a mature market with predictable demand.\u003c\/p\u003e\n\u003cp\u003eThe company's deep-rooted expertise and broad range of products solidify its competitive edge in this critical field of medical physics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStable Revenue and Improved Profitability in Dosimetry\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIBA's Dosimetry segment, despite some unevenness in the first half of 2024 due to global issues like anti-corruption drives in China, demonstrated a significant rebound.  The unit reported enhanced profitability and robust order intake in the first quarter of 2025, signaling its capacity for consistent cash generation.\u003c\/p\u003e\n\u003cp\u003eThis resilience makes Dosimetry a dependable source of financial stability for IBA. Its ability to secure strong orders, as seen in Q1 2025, underpins its role as a cash cow, contributing reliably to the group's overall financial health.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCritical Quality Assurance Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCritical Quality Assurance Solutions, specifically dosimetry, represent a significant cash cow for IBA. These solutions are absolutely vital for the accuracy and safety of radiation therapy, a non-negotiable aspect of patient care.  This fundamental need ensures a consistent demand for IBA's dosimetry products and services from hospitals and proton therapy centers worldwide.\u003c\/p\u003e\n\u003cp\u003eThe indispensable nature of dosimetry translates directly into a stable and high-margin revenue stream for IBA.  For instance, the global market for radiation therapy is projected to grow significantly, with dosimetry playing a key role in ensuring its efficacy and safety.  This steady demand, coupled with the essential function of these products, solidifies their cash cow status.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupport for Radiation Therapy Ecosystem\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe Dosimetry segment is a vital component of IBA's radiation therapy ecosystem, especially for its proton therapy offerings, by guaranteeing the quality and safety of treatments. This interdependence strengthens IBA's appeal as a provider of complete radiation therapy solutions.\u003c\/p\u003e\n\u003cp\u003eThe increasing global focus on accurate cancer treatment and the expanding market for radiation therapy, including proton therapy, ensure a steady demand for dosimetry services. This consistent need establishes dosimetry as a stable and dependable source of income for IBA.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eDosimetry ensures quality assurance in proton therapy.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eIt supports the entire radiation therapy business.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eDemand for quality control in radiation therapy is growing.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eDosimetry is a foundational and reliable revenue stream.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcquisition-led Portfolio Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eIBA's strategic expansion in Dosimetry, notably through the February 2024 acquisition of Radcal Corporation, exemplifies an acquisition-led growth strategy. This move significantly bolsters its medical imaging quality assurance capabilities and solidifies its footprint in the United States market.\u003c\/p\u003e\n\u003cp\u003eThe primary objective of this expansion is to drive revenue growth and achieve earnings before interest and taxes (EBIT) positivity within the Dosimetry segment. This positions Dosimetry as a key cash cow, contributing substantially to IBA's overall financial strength.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eRadcal Corporation Acquisition:\u003c\/strong\u003e Completed in February 2024, enhancing IBA's medical imaging quality assurance portfolio.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Strengthening:\u003c\/strong\u003e Deepened presence in the crucial US market.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFinancial Objectives:\u003c\/strong\u003e Aiming for revenue accretion and EBIT positivity in the Dosimetry segment.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eEnduring Strength:\u003c\/strong\u003e Integration of new technologies and expanded market reach contribute to sustained performance.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDosimetry: IBA's Reliable Revenue Generator\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe Dosimetry segment, a cornerstone of IBA's operations, functions as a significant cash cow. Its vital role in ensuring the safety and accuracy of radiation therapy, including proton therapy, guarantees a consistent and reliable revenue stream.\u003c\/p\u003e\n\u003cp\u003eThis segment's indispensable nature within the healthcare ecosystem, coupled with a growing global demand for precise cancer treatments, underpins its stable financial performance.\u003c\/p\u003e\n\u003cp\u003eIBA's strategic acquisitions, such as Radcal Corporation in February 2024, further bolster this segment's market position and revenue-generating capabilities, reinforcing its cash cow status.\u003c\/p\u003e\n\u003cp\u003eThe segment's resilience and consistent order intake, as evidenced by Q1 2025 results, highlight its dependable contribution to IBA's overall financial health.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eSegment\u003c\/td\u003e\n\u003ctd\u003eFY 2024 Revenue (€ millions)\u003c\/td\u003e\n\u003ctd\u003eKey Contribution\u003c\/td\u003e\n\u003ctd\u003eStrategic Development\u003c\/td\u003e\n\u003ctd\u003eOutlook\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDosimetry\u003c\/td\u003e\n\u003ctd\u003e65.9\u003c\/td\u003e\n\u003ctd\u003eQuality assurance in radiation therapy, stable demand\u003c\/td\u003e\n\u003ctd\u003eRadcal acquisition (Feb 2024) for US market expansion\u003c\/td\u003e\n\u003ctd\u003eContinued revenue growth and EBIT positivity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You’re Viewing Is Included\u003c\/span\u003e\u003cbr\u003eIBA BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe IBA BCG Matrix you are currently previewing is the identical, fully formatted document you will receive upon purchase. This means no watermarks, no demo content, and no surprises – just the complete strategic tool ready for your immediate use. You're getting precisely what you see, a professionally designed analysis ready for implementation in your business planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":55610797326713,"sku":"iba-worldwide-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/iba-worldwide-bcg-matrix.png?v=1754746381","url":"https:\/\/growthsharematrix.com\/products\/iba-worldwide-bcg-matrix","provider":"Growth Share Matrix","version":"1.0","type":"link"}